The European Commission’s proposed revision of its guideline on clinical trial authorisations has been largely welcomed by the pharmaceutical industry. However, most respondents to the consultation on the proposed changes to this crucial document say the commission could have supported the goal of harmonisation of clinical trial authorisations throughout the European Union even further1...
Please login to read the full article.
